Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) rose 0.7% during mid-day trading on Wednesday . The company traded as high as $9.99 and last traded at $9.81. Approximately 62,857 shares traded hands during mid-day trading, an increase of 301% from the average daily volume of 15,685 shares. The stock had previously closed at $9.74.
AlloVir Stock Performance
The firm has a 50 day simple moving average of $7.86 and a two-hundred day simple moving average of $5.32. The stock has a market cap of $49.47 million, a P/E ratio of -0.48 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Featured Stories
- Five stocks we like better than AlloVir
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
